Form 4: CorMedix COO Exercises Options, Sells Shares

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, exercised stock options and subsequently sold shares in pre-planned transactions.

Summary

• Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (CRMD), reported transactions involving the company's common stock.
• On September 9, 2025, Hurlburt acquired 12,876 shares of common stock by exercising stock options at a price of $1.45 per share.
• Immediately following, on September 9, 2025, she sold 12,876 shares of common stock at a weighted average price of $13.51 per share.
• On September 11, 2025, Hurlburt acquired an additional 41,121 shares of common stock by exercising stock options at a price of $1.45 per share.
• Concurrently, on September 11, 2025, she sold 41,121 shares of common stock at a weighted average price of $13.08 per share.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Hurlburt's direct beneficial ownership of common stock is 176,990 shares.
• The stock options exercised were granted on March 19, 2018, with an expiration date of March 19, 2028, and vested over four years and upon achievement of certain milestones.

Sentiment

Score: 5

Explanation: The transactions represent a routine exercise of stock options and subsequent sale of shares, likely for liquidity or tax purposes, under a pre-arranged 10b5-1 plan. This is a common practice for executives and does not inherently signal a strong positive or negative outlook for the company.

Positives

• The Chief Operating Officer exercised stock options at a low strike price of $1.45, indicating a significant in-the-money value for the options.
• The transactions were executed under a pre-arranged Rule 10b5-1(c) plan, suggesting a systematic approach to managing equity compensation rather than a reaction to immediate market conditions.

Negatives

• The Chief Operating Officer sold a total of 53,997 shares of common stock (12,876 + 41,121), which could be perceived as a reduction in insider ownership, although it was likely to cover the cost of exercise and taxes.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor impact due to the sale of shares, which slightly increases the float. The pre-planned nature mitigates concerns about insider sentiment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

CorMedix Inc., CRMD, Elizabeth Hurlburt, Chief Operating Officer, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Equity Compensation